Best of ACTHIV 2020: Recent Advances in HIV and What Comes Next

1. Review current state-of-the-art HIV treatment.
2. Describe advances in antiretroviral therapy that will enhance virologic activity, safety/tolerability, and convenience for patients.

The enduring material is jointly provided by Beaumont Health, American Academy of CME, Inc., and ACTHIV Institute.

The 14th Annual American Conference for the Treatment of HIV (ACTHIV) was held virtually August 20-22, 2020. The Conference was supported by the Clinical Education Initiative, New York State Department of Health, AIDS Institute. The conference and this Best of ACTHIV web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV HealthCare.

ONLINE CE CREDIT:

To obtain online CE credit, please follow this link to the course evaluation.

FACULTY:

Roy M. Gulick, MD, MPH,  Rochelle Belfer Professor in Medicine, Chief, Division of Infectious Diseases, Weill Cornell Medicine

Estimated time to complete: 45 minutes

TARGET AUDIENCE

Members of the HIV care team who are frontline providers of care to persons at risk for or are living with HIV infection, including physicians (both specialists and primary care/family medicine), nurse practitioners, physician assistants, nurses, pharmacists, case managers and other care team members are also encouraged to participate.

Learning Objectives

As a result of participating in this activity, participants should be better able to:

• Review current state-of-the-art HIV treatment.
• Describe advances in antiretroviral therapy that will enhance virologic activity, safety/tolerability, and convenience for patients

CREDIT

In support of improving patient care, this activity has been planned and implemented by Beaumont Health, American Academy of CME, Inc., and the ACTHIV Institute. Beaumont Health is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:

Beaumont Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc., Beaumont Health, and the ACTHIV Institute. Beaumont Health is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses Practitioners and Nurses: 

American Academy of CME, Inc. designates this educational activity for 0.75 contact hours (0.75 pharmacotherapeutic contact hours).

Physician Assistants:

American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until December 31, 2021. PAs should only claim credit commensurate with the extent of their participation.

All other members of the HIV Care team will receive a certificate of participation.

There is no fee to participate in this activity.

HOW TO RECEIVE CREDIT 

In order to obtain your certificate of credit, you must read the CME/CE information, review the full content of the activity, and complete the online evaluation.

Upon submission of the evaluation, your certificate for the activity will be made available immediately to print online.

DISCLOSURES

According to the disclosure policy of the Academy and Beaumont, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures will be made known to the participants prior to the activity. 

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, Beaumont, or ACTHIV Institute. This educational activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Off-Label Usage Disclosure

This activity contains off-label discussion.

Faculty Disclosure

R. M. Gulick, MD, MPH has no relevant financial relationships with commercial interests to disclose.

Planner Disclosures

The following individuals have no relevant financial relationships with commercial interests to disclose: Julie Barroso, PhD, ANP, FAAN; John Brooks, MD; Sherrillyn Crooks, PA-C; Carlos del Rio, MD; Courtney V Fletcher, PharmD; John JD Juchniewicz, MCIS, CHCP; Bill G Kapogiannis, MD; Deborah Kim, RPh; H. Nina Kim, MD, MSc; Natalie Kirkwood, RN, BSN, JD; Harry Lampiris, MD; Sharon Lee, MD; Vincent Lo Re, MD, MSCE; Lorenzo McFarland, DHA, MPH, MSW, PMP; Edward Moylan, RP; Paul Miniter, MS; Asa Radix, MD, MPH; Dianne Rausch, PhD; Renslow Sherer, MD; Cheryl Smith, MD; Brooke Taylor, MPH, CHCP; Andrea Weddle, MSW; Susan Weiss, FNP-BC, MSN, AAHIVS; Barbara A. Young, MSW, LCSE, LCADC, SAC

The following individuals have relevant financial relationships with commercial interests to disclose:

Oluwatoyin Adeyemi, MD: Advisory Board: Gilead Sciences; Grant/Research Support: Gilead Sciences 
Roger Bedimo, MD: Advisory Board: Merck & Co. & Co., ViiV Healthcare; Grant/Research Support: ViiV Healthcare
Michelle Cespedes, MD, MS: Advisory Board: Gilead Sciences, ViiV Healthcare 
Eric Daar, MD: Advisory Board: Gilead Sciences, ViiV Healthcare; Grant/Research Support: Gilead Sciences, Merck & Co., ViiV Healthcare 
Donna Futterman, MD: Grant/Research Support: Gilead Sciences 
Rajesh Gandhi, MD: Advisory Board: Merck & Co. 
Margaret Hoffman-Terry, MD, FACP, AAHIVS: Advisory Board: ViiV Healthcare; Grant/Research Support: ViiV Healthcare; Speaker's Bureau: Gilead Sciences, ViiV Healthcare 
Tonia Poteat, PhD, PA-C: Advisory Board: Gilead Sciences; Grant/Research Support: Gilead Sciences, ViiV Healthcare  
Jennifer C. Price, MD, PhD: Advisory Board: Surrozen, Theratechnologies; Shareholder (Spouse/Partner): Abbvie, Merck & Co., Bristol-Myers Squibb, Johnson & Johnson; Grant/Research Support: Gilead Sciences, Merck & Co. 
Jason Schafer, PharmD, MPH: Advisory Board: Merck & Co.; Grant/Research Support: Merck & Co., Gilead Sciences 
William Short, MD, MPH: Advisory Board: ViiV Healthcare 
Babafemi Taiwo, MBBS: Advisory Board: ViiV Healthcare, Gilead Sciences, Merck & Co. 
Pablo Tebas, MD: Advisory Board: Merck & Co., ViiV Healthcare, Gilead Sciences; Grant/Research Support: Merck & Co., ViiV Healthcare, Gilead Sciences, Inovio, Genone
Melanie Thompson, MD: Grant/Research Support: Bristol-Myers Squibb, Cytodyn, Cepheid, Gilead Sciences, GlaxoSmithKline, Merck & Co., ViiV Healthcare 

Privacy Policy

For more information about Beaumont’s privacy policy, please access https://www.beaumont.org/patients-families/patients-rights-privacy/privacy

For more information about the Academy’s privacy policy, please access http://www.academycme.org/privacy.htm

For questions related to physician credit, contact: cme@beaumont.edu  

For questions related to nursing (including NPs) and PA credit, contact CEservices@academycme.org

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later 
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2020 American Academy of CME, Inc., Beaumont Health, and ACTHIV Institute.

Resources:

• Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0
• IAS-USA Guidelines. https://www.iasusa.org/resources/guidelines/
• Venter WDF, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019;381(9):803-815.
• Venter F, Moorhouse M, Sokhela S, et al. The ADVANCE trial: Phase 3, randomised comparison of TAF/FTC+DTG, TDF/FTC+DTG or TDF/FTC/EFV for first-line treatment of HIV-1 infection. AIDS 2020: 23rd International AIDS Conference Virtual. July 6-10, 2020. Abstract OAXLB0104.  
• Koethe J. Greater weight gain after switch to InSTI-based regimen from NNRTI vs PI regimens. CROI 2020. March 8-11, 2020 ; Boston, MA. Abstract 668.
• Stanford Resistance Database. https://hivdb.stanford.edu/
• Cahn P, et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014;14:572-580.
• Sued O, et al. Dual therapy with darunavir/ritonavir plus lamivudine for HIV-1 treatment initiation: week 24 results of the randomized ANDES study. IAS 2017. July 23-26, 2017. Paris. Abstract #MOAB0106LB.
• Raffi L, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014;384:1942.
• Carr A, et al. Success and failure of initial antiretroviral therapy in adults: an updated systematic review. AIDS 2019;33:443-453.
• Kozal M, et al. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. NEJM. 2020;382:1232-43.
• Lataillade M, et al. Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug-resistant HIV-1 (BRIGHTE Study). IAS 2019. July 21-24, 2019. Mexico City. Abstract #MOAB0102.